

DOXYCYCLINE INHIBITS VASCULAR LEAKAGE AND PREVENTS THE DEVELOPMENT OF PULMONARY EDEMA

Ofer Fainaru^{*}, Irit Adini, Ofra Benny, Lauren Bazinet, Elke Pravda, Robert D'Amato and Judah Folkman¹

Vascular Biology Program at Children's Hospital Boston, Department of Surgery, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE DEC 2008		2. REPORT TYPE N/A		3. DATES COVERED -	
4. TITLE AND SUBTITLE Doxycycline Inhibits Vascular Leakage And Prevents The Development Of Pulmonary Edema				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Vascular Biology Program at Childrens Hospital Boston, Department of Surgery, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited					
13. SUPPLEMENTARY NOTES See also ADM002187. Proceedings of the Army Science Conference (26th) Held in Orlando, Florida on 1-4 December 2008					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 4	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

ABSTRACT

The Vascular Leak Syndrome induced by blast injuries, burns, asphyxiation, and other injuries lead to progressive pulmonary edema, as well as tissue and limb swelling that contribute to morbidity and mortality of soldiers on the battlefield. The main goal of our research is the development and validation of novel therapies to prevent and reverse vascular leak syndromes. Our findings indicate that doxycycline, a commonly used antibiotic, inhibits vascular leak in a spectrum of pathologies.

1. INTRODUCTION

The endothelium lining blood vessels serves as a barrier against vascular hyperpermeability, and its maintenance is critical to organ health. Inflammatory mediators evoke tissue edema by disrupting the expression of membrane junctional proteins, which mediate binding between endothelial cell membranes. Endothelial cell-cell junctions form a diffusion barrier between the intravascular and interstitial space. To prevent the morbidity and mortality caused by exaggerated vascular permeability associated with pathologic states (e.g., inflammatory and hypersensitivity disorders, pulmonary edema, traumatic lung injury, cerebral edema resulting from stroke and others), it is important to develop therapeutic approaches to stabilize these inter-endothelial junctions (Fainaru; Adini et al. 2008).

Tetracycline antibiotics are also potent inhibitors of the matrix metalloproteinase (MMP) proteins and have been used to reduce tissue degradation in arthritis and periodontal disease (Golub; Lee et al. 1998). Doxycycline, a tetracycline derivative, has been shown to inhibit angiogenesis in both humans and animal models; however, its antiangiogenic effect is MMP independent *in vitro*. We now tested the effect of this FDA-approved oral angiogenesis inhibitor on vascular permeability in mouse models of pulmonary edema and allergic skin reactions.

2. SELECTED METHODS

2.1 Miles vascular permeability assay

C57Bl/6J mice were treated with oral doxycycline (intragastric gavage) at the specified doses or vehicle for 3-5 days before the Miles assay was performed (Claffey; Brown et al. 1996; Miles; Miles 1952; Streit; Velasco et al. 2000). Of note, as it has been previously shown (Prall; Longo et al. 2002) that a doxycycline dose of 100 mg/kg/day achieved a mean plasma concentration similar to plasma levels of human patients taking the recommended dose of 200 mg / day. We therefore used a similar dosing range in all our *in vivo* experiments. For

the Miles assay, Evans blue dye (100 μ l of a 1% solution in 0.9% NaCl) was injected intravenously (i.v.) into mice. Evans blue dye binds to plasma proteins and leaks with them at sites of vessel permeability. After 10 min, 50 μ l of human VEGF₁₆₅ (1 ng/ μ l), PAF (100 μ M), histamine (1.2 μ g/ml), or PBS was injected intradermally into the pre-shaved back skin. After 20 min, the animals were sacrificed, and an area of skin that included the entire injection site was removed. Evans blue dye was extracted from the skin by incubation with formamide for 5 days at room temperature, and the absorbance of extracted dye was measured at 620 nm.

2.2 DTH reactions

DTH reactions were induced in the ears of 8-week-old C57Bl/6J male mice (n = 5) as previously described (Dvorak; Lett-Brown et al. 1984). Mice were sensitized by topical application of 2% oxazolone solution in vehicle (acetone:olive oil, 4:1 vol/vol), to the shaved abdomen (50 μ l). Mice were treated with oral doxycycline (80 mg/kg/day) for 5 days beginning on day 3, and after 5 days the right ears were challenged by topical application of 10 μ l of a 1% oxazolone solution; the left ears were treated with vehicle alone. Ear thickness was then measured daily as a measure of inflammation intensity (Gad; Dunn et al. 1986). Some mice from each experimental group were sacrificed 24 hr after oxazolone challenge. Their ears were fixed in 10% formalin and processed for H&E-stained paraffin sections.

2.3 IL-2-associated pulmonary edema

Mice were pretreated with oral doxycycline (80 mg/kg/day) or vehicle for 5 days. On the sixth day, mice received an intraperitoneal injection with IL-2 (1.2×10^6 units/100 μ l) or saline three times a day for 5 days. Doxycycline or vehicle treatment was continued through the course of IL-2 injections. At termination, mice were sacrificed, and lungs were dissected, weighed, fixed, and processed for H&E staining.

2.4 Permeability of endothelial monolayers

Endothelial permeability was analyzed *in vitro* by the diffusion of 2,000-kDa FITC-dextran through the endothelial monolayer (Chen; Pogue et al. 2006). Human microvascular endothelial cells (HMVECs) were grown on Transwell inserts (Costar, Cambridge, MA) up to confluence. The cells pretreated with doxycycline (20 μ M) for 16 hours. Medium containing 2.5 mg/ml 2,000-kDa FITC-dextran (Sigma, Sigma-Aldrich Inc, St. Louis, MO) was then loaded in the upper compartment of the Transwell. The amount of FITC-dextran diffused through the endothelial monolayer into the lower compartment was

measured by a microplate reader (Vactor³, PerkinElmer, Waltham, MA).

3. RESULTS

We first demonstrated (Fainaru; Adini et al. 2008) that doxycycline inhibited VEGF-induced vascular permeability in a dose-dependent manner using the *in vivo* vascular permeability (Miles) assay. This effect was comparable to that achieved by Bevacizumab (Avastin), a powerful inhibitor of VEGF action (Wedam; Low et al. 2006), in the same assay. When compared to tetracycline and other related compounds (i.e minocycline, chlorotetracycline), doxycycline was the most effective at preventing Evan's blue dye leakage.

In light of doxycycline's ability to prevent vascular permeability, we tested mouse models of clinical conditions where vascular leak serves a major source of morbidity. Immunotherapy with IL-2 represents an important modality in the management of human metastatic renal cell carcinoma and malignant melanoma, however, this effective treatment is often limited by myriad complications, mainly due to a vascular leak syndrome resulting in pulmonary edema (Berthiaume; Boiteau et al. 1995). To explore the possibility that doxycycline may prevent this potentially lethal complication, mice were pretreated with oral doxycycline (80 mg/kg/day) or vehicle for four days before administering intraperitoneal IL-2 for five days in the continued presence of drug. IL-2 treated mice developed severe pulmonary edema, as demonstrated by a 2.75 fold increase in wet lung weight when compared to vehicle treated controls. Histological sections of the lungs from control mice revealed severe congestion and edema with intra-alveolar fibrin deposition, as well as perivascular and peribronchial mononuclear cell infiltrates. Impressively, doxycycline almost completely inhibited the IL-2 induced increase in lung weight and prevented tissue edema, without producing any evidence of systemic toxicity or weight loss. Our results thus show that IL-2 induced pulmonary edema may be effectively prevented by oral administration of the FDA-approved drug, doxycycline.

The delayed type hypersensitivity reaction (DTH) is also characterized by enhanced vascular permeability and edema formation (Asherson; Ptak 1968), and thus we tested whether doxycycline can inhibit this reaction in a mouse model of contact dermatitis. Mice were sensitized by applying the hapten oxazolone to their abdominal skin, and then were treated either with oral doxycycline (80 mg/kg/day) or vehicle beginning on day 3 after sensitization. Six days after sensitization we challenged the mice by application of oxazolone or vehicle to the right and left ears respectively. Mice treated with doxycycline exhibited significantly reduced ($p < 0.05$)

erythema and ear swelling compared with vehicle-treated control mice at 24, 36 and 48 hours. Doxycycline may thus prove to be of value in treating allergic conditions also in humans.

Of the molecular structures comprising the endothelial cell-cell contacts, the adherens junctions, composed of cadherins and catenins, are the primary adhesions between the cells and they are essential for barrier integrity (Lampugnani; Dejana 1997). At the endothelial adherens junction, the key transmembrane protein is VE-cadherin, which clusters together in these regions and mediates cell-cell adhesion through homophilic binding to other VE-cadherins expressed on adjacent endothelial cells (Gumbiner 1996; Lampugnani; Resnati et al. 1992). Paracellular permeability induced by inflammatory mediators, such as VEGF, is accompanied by disruption of the VE-cadherin/catenin complex and loss of cadherin from the cell borders. In fact, disruption of cadherins within the adherens junction mediates the increase in permeability and lung edema that are induced by inflammatory stimuli. Our results show that doxycycline treatment increases the expression of VE-cadherin at the intercellular junctions of human dermal endothelial cells *in vitro*, without significantly altering the expression of β catenin or ZO-1. This effect on VE-cadherin expression may be responsible for the increased barrier function of the endothelium and the decreased protein leak observed *in vivo*.

4. CONCLUSIONS

Taken together, our results indicate that doxycycline may prove useful as a potent oral anti-vascular permeability drug. The mechanism for this effect appears to be upregulation of VE-cadherin at the adherens junctions, thereby enhancing intercellular adhesion and improving the barrier function of the endothelium. Data from these mouse studies may serve as basis for future translation of this therapy into clinical testing. The use of this oral FDA-approved drug to prevent or treat pulmonary vascular leak syndromes as a result of trauma or other injuries sustained during combat, may allow rapid self-treatment by soldiers or other wounded personnel, and might potentially be used as prophylaxis before entering into battle.

5. ACKNOWLEDGEMENTS

This research was supported by the Fulbright and Rothschild Foundations and the European Molecular Biology Organization (EMBO) Fellowship (O.F), Department of Defense Award W81XWH-05-1-0115 (to J.F.).

6. REFERENCES

- Asherson, G. L. and W. Ptak, 1968: Contact and delayed hypersensitivity in the mouse. I. Active sensitization and passive transfer. *Immunology*, **15**, 405-16.
- Berthiaume, Y., P. Boiteau, G. Fick, R. Kloiber, G. D. Sinclair, C. Fong, M. C. Poon, and R. Lafreniere, 1995: Pulmonary edema during IL-2 therapy: combined effect of increased permeability and hydrostatic pressure. *Am J Respir Crit Care Med*, **152**, 329-35.
- Chen, B., B. W. Pogue, J. M. Luna, R. L. Hardman, P. J. Hoopes, and T. Hasan, 2006: Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. *Clin Cancer Res*, **12**, 917-23.
- Claffey, K. P., L. F. Brown, L. F. del Aguila, K. Tognazzi, K. T. Yeo, E. J. Manseau, and H. F. Dvorak, 1996: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. *Cancer Res*, **56**, 172-81.
- Dvorak, A. M., M. A. Lett-Brown, D. O. Thueson, K. Pyne, P. K. Raghuprasad, S. J. Galli, and J. A. Grant, 1984: Histamine-releasing activity (HRA). III. HRA induces human basophil histamine release by provoking noncytotoxic granule exocytosis. *Clin Immunol Immunopathol*, **32**, 142-50.
- Fainaru, O., I. Adini, O. Benny, L. Bazinet, E. Pravda, R. D'Amato, and J. Folkman, 2008: Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. *Faseb J*.
- Gad, S. C., B. J. Dunn, D. W. Dobbs, C. Reilly, and R. D. Walsh, 1986: Development and validation of an alternative dermal sensitization test: the mouse ear swelling test (MEST). *Toxicol Appl Pharmacol*, **84**, 93-114.
- Golub, L. M., H. M. Lee, M. E. Ryan, W. V. Giannobile, J. Payne, and T. Sorsa, 1998: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. *Adv Dent Res*, **12**, 12-26.
- Gumbiner, B. M., 1996: Cell adhesion: the molecular basis of tissue architecture and morphogenesis. *Cell*, **84**, 345-57.
- Lampugnani, M. G. and E. Dejana, 1997: Interendothelial junctions: structure, signalling and functional roles. *Curr Opin Cell Biol*, **9**, 674-82.
- Lampugnani, M. G., M. Resnati, M. Raiteri, R. Pigott, A. Pisacane, G. Houen, L. P. Ruco, and E. Dejana, 1992: A novel endothelial-specific membrane protein is a marker of cell-cell contacts. *J Cell Biol*, **118**, 1511-22.
- Miles, A. A. and E. M. Miles, 1952: Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. *J Physiol*, **118**, 228-57.
- Prall, A. K., G. M. Longo, W. G. Mayhan, E. A. Waltke, B. Fleckten, R. W. Thompson, and B. T. Baxter, 2002: Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. *J Vasc Surg*, **35**, 923-9.
- Streit, M., P. Velasco, L. Riccardi, L. Spencer, L. F. Brown, L. Janes, B. Lange-Asschenfeldt, K. Yano, T. Hawighorst, L. Iruela-Arispe, and M. Detmar, 2000: Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. *Embo J*, **19**, 3272-82.
- Wedam, S. B., J. A. Low, S. X. Yang, C. K. Chow, P. Choyke, D. Danforth, S. M. Hewitt, A. Berman, S. M. Steinberg, D. J. Liewehr, J. Plehn, A. Doshi, D.
- Thomasson, N. McCarthy, H. Koeppen, M. Sherman, J. Zujewski, K. Camphausen, H. Chen, and S. M. Swain, 2006: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. *J Clin Oncol*, **24**, 769-77.